Advertisement

Serum apoptosis markers in HIV-infected patients with human herpesvirus type 8 and herpes simplex virus type 2 co-infection

  • O. Dakovic RodeEmail author
  • A. Markotic
  • M. Kujundzic Tiljak
  • S. Zidovec Lepej
  • J. Begovac
Article
  • 171 Downloads

Abstract

This study aimed to examine the influence of human herpesvirus type 8 (HHV-8) and herpes simplex virus type 2 (HSV-2) co-infections on apoptosis serum markers in human immunodeficiency virus (HIV)-infected patients. Sera from 110 HIV-infected and 59 HIV-uninfected individuals were analyzed for soluble Fas (sFas), sFas ligand (sFasL), caspase-8, and Bcl-2. The findings of HIV-infected patients with no co-infection (n = 37), HIV-infected patients with HHV-8 co-infection (n = 22), HIV-infected patients with HSV-2 co-infection (n = 51), and patients with HSV-2 co-infection and no HIV infection (n = 20) were compared to controls (reference group) with no HIV, HSV-2, and HHV-8 co-infections (n = 39). Soluble Fas and sFasL concentrations were the highest in HIV and HHV-8 co-infected patients (medians, 912.7 pg/ml and 74.3 pg/mL, respectively). No difference in caspase-8 concentrations was found, whereas Bcl-2 concentrations were the highest in HIV and HHV-8 co-infected individuals. Older age was associated with higher sFas (p < 0.001) and lower sFasL (p = 0.04) concentrations. In a robust regression model adjusted for age, the log-transformed sFas concentrations were significantly lower in HIV-infected patients with no co-infections (β = −0.244; p < 0.001) and higher in HIV and HHV-8 co-infected patients (β = 0.216; p = 0.012) compared to the reference group. Soluble FasL was significantly lower in HIV-infected patients with no co-infections (β = −0.284; p = 0.005) and in HIV-infected patients with HSV-2 co-infection (β = −0.381; p < 0.001) compared to the reference group. Soluble FasL was also higher in HIV and HHV-8 co-infected patients compared to controls (β = 0.248; p = 0.036). Our results suggest that HHV-8 and HSV-2 may have a significant effect on Fas–FasL-mediated apoptosis in HIV-1 patients. HHV-8 upregulates while HSV-2 downregulates sFas and sFasL.

Keywords

Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Human Immunodeficiency Virus Patient Soluble FasL sFas Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest

The authors declare no conflicts of interest.

References

  1. 1.
    Cummins NW, Badley AD (2010) Mechanisms of HIV-associated lymphocyte apoptosis: 2010. Cell Death Dis 1:e99. doi: 10.1038/cddis.2010.77 PubMedCrossRefGoogle Scholar
  2. 2.
    Sloand EM, Young NS, Kumar P, Weichold FF, Sato T, Maciejewski JP (1997) Role of Fas ligand and receptor in the mechanism of T-cell depletion in acquired immunodeficiency syndrome: effect on CD4+ lymphocyte depletion and human immunodeficiency virus replication. Blood 89:1357–1363PubMedGoogle Scholar
  3. 3.
    Dianzani U, Bensi T, Savarino A, Sametti S, Indelicato M, Mesturini R, Chiocchetti A (2003) Role of FAS in HIV infection. Curr HIV Res 1:405–417PubMedCrossRefGoogle Scholar
  4. 4.
    Nagata S (1994) Fas and Fas ligand: a death factor and its receptor. Adv Immunol 57:129–144PubMedCrossRefGoogle Scholar
  5. 5.
    Ferguson TA, Griffith TS (2006) A vision of cell death: Fas ligand and immune privilege 10 years later. Immunol Rev 213:228–238PubMedCrossRefGoogle Scholar
  6. 6.
    Hohlbaum AM, Saff RR, Marshak-Rothstein A (2002) Fas-ligand—iron fist or Achilles’ heel? Clin Immunol 103:1–6PubMedCrossRefGoogle Scholar
  7. 7.
    Ottonello L, Tortolina G, Amelotti M, Dallegri F (1999) Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J Immunol 162:3601–3606PubMedGoogle Scholar
  8. 8.
    Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759–1762PubMedCrossRefGoogle Scholar
  9. 9.
    Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G (1996) An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 156:4622–4630PubMedGoogle Scholar
  10. 10.
    Albanese J, Meterissian S, Kontogiannea M, Dubreuil C, Hand A, Sorba S, Dainiak N (1998) Biologically active Fas antigen and its cognate ligand are expressed on plasma membrane-derived extracellular vesicles. Blood 91:3862–3874PubMedGoogle Scholar
  11. 11.
    Osman HG, Gabr OM, Lotfy S, Gabr S (2007) Serum levels of bcl-2 and cellular oxidative stress in patients with viral hepatitis. Indian J Med Microbiol 25:323–329PubMedCrossRefGoogle Scholar
  12. 12.
    Ashley RL, Wald A (1999) Genital herpes: review of the epidemic and potential use of type-specific serology. Clin Microbiol Rev 12:1–8PubMedGoogle Scholar
  13. 13.
    Chatterjee K, Dandara C, Gyllensten U, van der Merwe L, Galal U, Hoffman M, Williamson AL (2010) A Fas gene polymorphism influences herpes simplex virus type 2 infection in South African women. J Med Virol 82:2082–2086PubMedCrossRefGoogle Scholar
  14. 14.
    Sieg S, Yildirim Z, Smith D, Kayagaki N, Yagita H, Huang Y, Kaplan D (1996) Herpes simplex virus type 2 inhibition of Fas ligand expression. J Virol 70:8747–8751PubMedGoogle Scholar
  15. 15.
    Krzyzowska M, Schollenberger A, Niemiałtowski MG (2000) How human immunodeficiency viruses and herpesviruses affect apoptosis. Acta Virol 44:203–210PubMedGoogle Scholar
  16. 16.
    Lapinski TW, Jaroszewicz J, Wiercinska-Drapalo A (2006) Concentrations of soluble Fas and soluble Fas ligand as indicators of programmed cell death among patients coinfected with Human Immunodeficiency Virus and Hepatitis C Virus. Viral Immunol 19:570–575PubMedCrossRefGoogle Scholar
  17. 17.
    Mandy FF, Nicholson JK, McDougal JS; CDC (2003) Guidelines for performing single-platform absolute CD4+ T-cell determinations with CD45 gating for persons infected with human immunodeficiency virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 52:1–13PubMedGoogle Scholar
  18. 18.
    Rezaee SA, Cunningham C, Davison AJ, Blackbourn DJ (2006) Kaposi’s sarcoma-associated herpesvirus immune modulation: an overview. J Gen Virol 87:1781–1804PubMedCrossRefGoogle Scholar
  19. 19.
    Lapinski TW, Kowalczuk O, Prokopowicz D, Chyczewski L (2004) Serum concentration of sFas and sFasL in healthy HBsAg carriers, chronic viral hepatitis B and C patients. World J Gastroenterol 10:3650–3653PubMedGoogle Scholar
  20. 20.
    Guzmán-Fulgencio M, Berenguer J, García-Álvarez M, Micheloud D, López JC, Cosín J, Fernández de Castro I, Catalán P, Miralles P, Resino S (2011) Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy. Eur J Clin Microbiol Infect Dis 30(10):1213–1221PubMedCrossRefGoogle Scholar
  21. 21.
    Lapiński TW, Kovalczuk O, Flisiak R, Pancewicz J (2006) Levels of HBV-DNA, sFas and sFasL among healthy HBsAg carriers in period of three years. Adv Med Sci 51:46–50PubMedGoogle Scholar
  22. 22.
    Jodo S, Kobayashi S, Nakajima Y, Matsunaga T, Nakayama N, Ogura N, Kayagaki N, Okumura K, Koike T (1998) Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol 112:166–171PubMedCrossRefGoogle Scholar
  23. 23.
    Sciortino MT, Perri D, Medici MA, Grelli S, Serafino A, Borner C, Mastino A (2006) Role of Bcl-2 expression for productive herpes simplex virus 2 replication. Virology 356:136–146PubMedCrossRefGoogle Scholar
  24. 24.
    Bélanger C, Gravel A, Tomoiu A, Janelle ME, Gosselin J, Tremblay MJ, Flamand L (2001) Human herpesvirus 8 viral FLICE-inhibitory protein inhibits Fas-mediated apoptosis through binding and prevention of procaspase-8 maturation. J Hum Virol 4:62–73PubMedGoogle Scholar
  25. 25.
    Lamkanfi M, Festjens N, Declercq W, Vanden Berghe T, Vandenabeele P (2007) Caspases in cell survival, proliferation and differentiation. Cell Death Differ 14:44–55PubMedCrossRefGoogle Scholar
  26. 26.
    Begovac J, Zekan A, Skoko-Poljak D (2006) Twenty years of human immunodeficiency virus infection in Croatia—an epidemic that is still in an early stage. Coll Antropol 30(Suppl 2):17–23PubMedGoogle Scholar
  27. 27.
    Rode OD, Lepej SZ, Begovac J (2005) Low seroprevalence of human herpesvirus 8 infection in Croatia. Clin Infect Dis 40:1208PubMedCrossRefGoogle Scholar
  28. 28.
    Rode OD, Lepej SZ, Begovac J (2008) Seroprevalence of herpes simplex virus type 2 in adult HIV-infected patients and blood donors in Croatia. Coll Antropol 32:693–695PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • O. Dakovic Rode
    • 1
    Email author
  • A. Markotic
    • 1
  • M. Kujundzic Tiljak
    • 2
    • 3
  • S. Zidovec Lepej
    • 1
  • J. Begovac
    • 1
    • 2
  1. 1.University Hospital for Infectious Diseases “Dr. Fran Mihaljevic”ZagrebCroatia
  2. 2.University of Zagreb, School of MedicineZagrebCroatia
  3. 3.Andrija Štampar School of Public HealthZagrebCroatia

Personalised recommendations